Vasopressin in the Amelioration of Social Functioning in Autism Spectrum Disorder
- PMID:31331023
- PMCID: PMC6678231
- DOI: 10.3390/jcm8071061
Vasopressin in the Amelioration of Social Functioning in Autism Spectrum Disorder
Abstract
Autism spectrum disorder (ASD) is a developmental disability described by diagnostic criteria that comprise deficits in social communication and the existence of repetitive, restricted patterns of behavior, interests, or activities that can last throughout life. Many preclinical studies show the importance of arginine vasopressin (AVP) physiology in social functioning in several mammalian species. Currently, there is a trend to investigate more specific pharmacological agents to improve social functioning in patients with ASD. Neurobiological systems that are crucial for social functioning are the most encouraging conceivable signaling pathways for ASD therapeutic discovery. The AVP signaling pathway is one of the most promising. The purpose of this commentary is to detail the evidence on the use of AVP as an agent that can improve social functioning. The pharmacologic aspects of the drug as well as its potential to ameliorate social functioning characteristics in human and animal studies are described in this manuscript. AVP, especially in its inhaled form, seems to be safe and beneficial in improving social functioning including in children with autism. Larger randomized studies are required to implement a long awaited safe and feasible treatment in people with a deficiency in social functioning.
Keywords: autism; functioning; social; vasopressin.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
- The Role of the Oxytocin/Arginine Vasopressin System in Animal Models of Autism Spectrum Disorder.Zhang R, Xu XJ, Zhang HF, Han SP, Han JS.Zhang R, et al.Adv Anat Embryol Cell Biol. 2017;224:135-158. doi: 10.1007/978-3-319-52498-6_8.Adv Anat Embryol Cell Biol. 2017.PMID:28551755Review.
- Genes Related to Oxytocin and Arginine-Vasopressin Pathways: Associations with Autism Spectrum Disorders.Zhang R, Zhang HF, Han JS, Han SP.Zhang R, et al.Neurosci Bull. 2017 Apr;33(2):238-246. doi: 10.1007/s12264-017-0120-7. Epub 2017 Mar 10.Neurosci Bull. 2017.PMID:28283809Free PMC article.Review.
- Arginine Vasopressin Is a Blood-Based Biomarker of Social Functioning in Children with Autism.Carson DS, Garner JP, Hyde SA, Libove RA, Berquist SW, Hornbeak KB, Jackson LP, Sumiyoshi RD, Howerton CL, Hannah SL, Partap S, Phillips JM, Hardan AY, Parker KJ.Carson DS, et al.PLoS One. 2015 Jul 22;10(7):e0132224. doi: 10.1371/journal.pone.0132224. eCollection 2015.PLoS One. 2015.PMID:26200852Free PMC article.
- Systematic Review of Literature on Single-Nucleotide Polymorphisms Within the Oxytocin and Vasopressin Receptor Genes in the Development of Social Cognition Dysfunctions in Individuals Suffering From Autism Spectrum Disorder.Wilczyński KM, Siwiec A, Janas-Kozik M.Wilczyński KM, et al.Front Psychiatry. 2019 May 31;10:380. doi: 10.3389/fpsyt.2019.00380. eCollection 2019.Front Psychiatry. 2019.PMID:31214061Free PMC article.
- A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.Umbricht D, Del Valle Rubido M, Hollander E, McCracken JT, Shic F, Scahill L, Noeldeke J, Boak L, Khwaja O, Squassante L, Grundschober C, Kletzl H, Fontoura P.Umbricht D, et al.Neuropsychopharmacology. 2017 Aug;42(9):1914-1923. doi: 10.1038/npp.2016.232. Epub 2016 Oct 6.Neuropsychopharmacology. 2017.PMID:27711048Free PMC article.Clinical Trial.
Cited by
- A Spectrum of Solutions: Unveiling Non-Pharmacological Approaches to Manage Autism Spectrum Disorder.Mondal A, Sharma R, Abiha U, Ahmad F, Karan A, Jayaraj RL, Sundar V.Mondal A, et al.Medicina (Kaunas). 2023 Aug 31;59(9):1584. doi: 10.3390/medicina59091584.Medicina (Kaunas). 2023.PMID:37763703Free PMC article.Review.
- Multiple Aspects of Inappropriate Action of Renin-Angiotensin, Vasopressin, and Oxytocin Systems in Neuropsychiatric and Neurodegenerative Diseases.Szczepanska-Sadowska E, Wsol A, Cudnoch-Jedrzejewska A, Czarzasta K, Żera T.Szczepanska-Sadowska E, et al.J Clin Med. 2022 Feb 9;11(4):908. doi: 10.3390/jcm11040908.J Clin Med. 2022.PMID:35207180Free PMC article.Review.
- Persistent autism-relevant behavioral phenotype and social neuropeptide alterations in female mice offspring induced by maternal transfer of PBDE congeners in the commercial mixture DE-71.Kozlova EV, Valdez MC, Denys ME, Bishay AE, Krum JM, Rabbani KM, Carrillo V, Gonzalez GM, Lampel G, Tran JD, Vazquez BM, Anchondo LM, Uddin SA, Huffman NM, Monarrez E, Olomi DS, Chinthirla BD, Hartman RE, Kodavanti PRS, Chompre G, Phillips AL, Stapleton HM, Henkelmann B, Schramm KW, Curras-Collazo MC.Kozlova EV, et al.Arch Toxicol. 2022 Jan;96(1):335-365. doi: 10.1007/s00204-021-03163-4. Epub 2021 Oct 23.Arch Toxicol. 2022.PMID:34687351Free PMC article.
- Rethinking the Architecture of Attachment: New Insights into the Role for Oxytocin Signaling.Berendzen KM, Manoli DS.Berendzen KM, et al.Affect Sci. 2022 Oct 17;3(4):734-748. doi: 10.1007/s42761-022-00142-5. eCollection 2022 Dec.Affect Sci. 2022.PMID:36519145Free PMC article.Review.
- Acute, chronic and conditioned effects of intranasal oxytocin in the mu-opioid receptor knockout mouse model of autism: Social context matters.Pantouli F, Pujol CN, Derieux C, Fonteneau M, Pellissier LP, Marsol C, Karpenko J, Bonnet D, Hibert M, Bailey A, Le Merrer J, Becker JAJ.Pantouli F, et al.Neuropsychopharmacology. 2024 Nov;49(12):1934-1946. doi: 10.1038/s41386-024-01915-1. Epub 2024 Jul 17.Neuropsychopharmacology. 2024.PMID:39020142Free PMC article.
References
- American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 5th ed. BMC Med.; Arlington, VA, USA: 2013.
- Baio J., Wiggins L., Christensen D.L., Maenner M.J., Daniels J., Warren Z., Kurzius-Spencer M., Zahorodny W., Rosenberg C.R., White T., et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014. MMWR Surveill. Summ. 2018;67:1–23. doi: 10.15585/mmwr.ss6706a1. - DOI - PMC - PubMed
- Autistic Spectrum Disorders Center for Disease Control and Prevention. [(accessed on 3 August 2018)]; Available online:https://www.cdc.gov/ncbddd/autism/data.html.
- Ronald A., Happé F., Bolton P., Butcher L.M., Price T.S., Wheelwright S., Baron-Cohen S., Plomin R. Genetic heterogeneity between the three components of the autism spectrum: A twin study. J. Am. Acad. Child Adolesc. Psychiatry. 2006;45:691–699. doi: 10.1097/01.chi.0000215325.13058.9d. - DOI - PubMed
Publication types
Related information
LinkOut - more resources
Full Text Sources
Miscellaneous